Free Trial
NASDAQ:ARDX

Ardelyx (ARDX) Stock Price, News & Analysis

Ardelyx logo
$3.97 +0.01 (+0.25%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$3.96 -0.01 (-0.13%)
As of 05/23/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ardelyx Stock (NASDAQ:ARDX)

Key Stats

Today's Range
$3.86
$4.00
50-Day Range
$3.28
$5.51
52-Week Range
$3.21
$8.06
Volume
2.57 million shs
Average Volume
4.46 million shs
Market Capitalization
$949.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.39
Consensus Rating
Moderate Buy

Company Overview

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Ardelyx Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
88th Percentile Overall Score

ARDX MarketRank™: 

Ardelyx scored higher than 88% of companies evaluated by MarketBeat, and ranked 101st out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ardelyx has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Ardelyx has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Ardelyx's stock forecast and price target.
  • Earnings Growth

    Earnings for Ardelyx are expected to grow in the coming year, from ($0.18) to $0.31 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ardelyx is -24.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ardelyx is -24.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ardelyx has a P/B Ratio of 5.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Ardelyx's valuation and earnings.
  • Percentage of Shares Shorted

    12.46% of the outstanding shares of Ardelyx have been sold short.
  • Short Interest Ratio / Days to Cover

    Ardelyx has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Ardelyx has recently decreased by 1.23%, indicating that investor sentiment is improving.
  • Dividend Yield

    Ardelyx does not currently pay a dividend.

  • Dividend Growth

    Ardelyx does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.46% of the outstanding shares of Ardelyx have been sold short.
  • Short Interest Ratio / Days to Cover

    Ardelyx has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Ardelyx has recently decreased by 1.23%, indicating that investor sentiment is improving.
  • News Sentiment

    Ardelyx has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for Ardelyx this week, compared to 9 articles on an average week.
  • Search Interest

    Only 6 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • MarketBeat Follows

    Only 8 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ardelyx insiders have bought 149.62% more of their company's stock than they have sold. Specifically, they have bought $2,327,056.00 in company stock and sold $932,254.00 in company stock.

  • Percentage Held by Insiders

    Only 4.80% of the stock of Ardelyx is held by insiders.

  • Percentage Held by Institutions

    58.92% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ardelyx's insider trading history.
Receive ARDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter.

ARDX Stock News Headlines

$19 for a FULL YEAR of stock picks?!
Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. Discover how a $100 investment could give you exposure to Musk's private AI project — via one overlooked stock.
See More Headlines

ARDX Stock Analysis - Frequently Asked Questions

Ardelyx's stock was trading at $5.07 at the beginning of 2025. Since then, ARDX shares have decreased by 21.7% and is now trading at $3.97.
View the best growth stocks for 2025 here
.

Ardelyx, Inc. (NASDAQ:ARDX) released its quarterly earnings results on Thursday, May, 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.07. The company's quarterly revenue was up 61.1% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of Ardelyx include Vanguard Group Inc. (6.27%), Millennium Management LLC (2.70%), Nuveen LLC (1.42%) and Goldman Sachs Group Inc. (0.99%). Insiders that own company stock include David M Mott, Michael Raab, Justin A Renz, Laura A Williams, Susan Rodriguez, Robert Blanks, Eric Duane Foster, Elizabeth A Grammer, Mike Kelliher, David P Rosenbaum and Robert Ora Felsch.
View institutional ownership trends
.

Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ardelyx investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), e.l.f. Beauty (ELF), GE Aerospace (GE), Builders FirstSource (BLDR) and ServiceNow (NOW).

Company Calendar

Last Earnings
5/01/2025
Today
5/24/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARDX
Employees
90
Year Founded
2007

Price Target and Rating

Average Stock Price Target
$10.39
High Stock Price Target
$15.00
Low Stock Price Target
$5.50
Potential Upside/Downside
+161.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-39,140,000.00
Pretax Margin
-11.65%

Debt

Sales & Book Value

Annual Sales
$361.71 million
Price / Cash Flow
N/A
Book Value
$0.73 per share
Price / Book
5.44

Miscellaneous

Free Float
222,880,000
Market Cap
$949.84 million
Optionable
Optionable
Beta
0.76

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ARDX) was last updated on 5/24/2025 by MarketBeat.com Staff
From Our Partners